Anaplastic large cell lymphoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 20: | Line 20: | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
Revision as of 17:17, 14 August 2015
Anaplastic large cell lymphoma Microchapters |
Differentiating Anaplastic large cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Anaplastic large cell lymphoma medical therapy On the Web |
American Roentgen Ray Society Images of Anaplastic large cell lymphoma medical therapy |
Directions to Hospitals Treating Anaplastic large cell lymphoma |
Risk calculators and risk factors for Anaplastic large cell lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
- Managed under "Aggressive Lymphoma" guidelines
- CHOP is first line of treatment, CHOP-Rituxan in the unlikely scenario that CD20 is positive, given that CD20 is a B-cell marker.
- Radiation therapy as per institutional preference (based on ECOG, SWOG, and GELA trials), but usually added for bulky disease
- Overall better prognosis than other "Aggressive Lymphomas"
- ALK+ 5-year survival 70-80%
- ALK- 5-year survival 30-40%